Staphylococcus epidermidis (LRSE) and linezolid-dependent ST22 strains have been shown to predominate in tertiary care facilities all over Greece. We report herein the dissemination of ST22 but also ST2, ST5 and ST168 linezolid-dependent LRSE clones in four unrelated German hospitals.
Introduction
Linezolid, the first oxazolidinone drug, was launched in 2001 and is still displaying excellent in vitro activity against Staphylococcus epidermidis on a global scale, 1 although outbreaks of linezolidresistant S. epidermidis (LRSE) are occasionally reported.
2,3 LRSE clinical isolates have been described to exhibit partial dependence on linezolid, with significant growth acceleration under linezolid exposure. 4 This growth characteristic was attributed to structural and functional adaptations of ribosomes as a result of linezolid binding and confers a selective advantage on LRSE strains that are exposed to linezolid. 5 We recently showed that LRSE became quite common in ICUs throughout Greece, with the vast majority of isolates exhibiting dependence on linezolid and belonging to ST22, 6 which implies that the expansion of linezolid resistance was probably driven by this trait. LRSE emerged and were reported to cause outbreaks also in German hospitals, with most of the strains also belonging to ST22. 7 The current study aimed to test the hypothesis that linezolid-dependent LRSE (ST22 or other lineages) also exist and may contribute to the dissemination of linezolid resistance in German hospitals.
Materials and methods

Bacterial isolates and susceptibility testing
The study included 14 LRSE clinical isolates recovered between 2012 and 2014 from five distantly located German hospitals (Lower Saxony, (bioMérieux, Marcy-l'Étoile, France) was used to confirm the result. In all phenotypic assays, Staphylococcus aureus strain ATCC 29213 (linezolid MIC 0.5 mg/L) was used as a control strain.
Growth characteristics of bacterial isolates
Bacterial growth rates were determined in triplicate, as described previously. 4 All 14 LRSE study isolates were tested without and with linezolid at 16 and 32 mg/L and at 0.25 mg/L for the strain ATCC 29213. These linezolid concentrations were selected according to previous studies on linezolid-dependent LRSE. [4] [5] [6] The growth rates of the isolates without and with linezolid were statistically compared using the paired t-test and the v 2 test; P values ,0.05 indicated significance and statistical analyses were performed with Minitab software (version 13.31) and SPSS software (version 17; SPSS Inc., Chicago, IL, USA).
Typing and molecular testing for linezolid resistance mechanisms
The 14 LRSE were genotyped by MLST as described previously. 8 They were tested by PCR for the presence of the cfr gene; 7 mutations in the peptidyltransferase centre and in riboproteins L3, L4 and L22 possibly conferring linezolid resistance were identified by PCR/sequencing. Layer et al.
Results
Four and six LRSE isolates, respectively, were recovered during LRSE outbreaks in two distinct German hospitals. The larger outbreak, which involved six LRSE, was preceded by a considerable increase in linezolid consumption for the treatment of MRSA infections. The remaining four isolates came from three different hospitals. The phenotypic and genotypic characteristics of the study isolates are shown in Table 1 . In brief, of the 14 LRSE clinical isolates tested, most (11, 78.6%) exhibited high-level resistance, with linezolid MICs being .256 mg/L. Five isolates carried the cfr gene. As for the clonal composition of the isolates, eight belonged to ST22, two isolates each to ST2 and ST168, one isolate to ST5 and one to ST23. Diverse and complex linezolid resistance mechanisms were identified among the LRSE, including new and already described mutations in 23S rRNA and mutations in the associated ribosomal proteins that may affect linezolid activity. In particular, all 14 isolates harboured at least one 23S rRNA mutation, 11 at least one mutation in L3, 10 at least one mutation in L4 and none displayed mutations in L22.
Bacterial growth rates indicated that nine isolates (seven belonging to ST22 and one to each of ST2 and ST5) exhibited significant (P , 0.05) linezolid-dependent growth at both 16 and 32 mg/L linezolid and four isolates were linezolid-non-dependent (one belonging to each of ST22, ST2, ST23 and ST168). One isolate (14-02427, ST168) repeatedly exhibited an unusual mode of growth, being linezolid-non-dependent up to 12 h of growth, but clearly linezolid-dependent at 24-36 h of linezolid exposure, as indicated by significantly faster growth with than without linezolid exposure. Growth curves of a representative linezolid-dependent and a linezolid-non-dependent isolate are shown in Figure 1 .
Discussion
Linezolid resistance among S. epidermidis is still uncommon worldwide; however, LRSE are increasingly reported from Europe 4, 6, 7, [9] [10] [11] [12] and occasionally cause outbreaks. In a multicentre study from Greece, LRSE were quite common, particularly in ICUs, where during 2013 resistance rates reached 20.9% 6 and, of note, the majority of LRSE belonged to ST22. The emergence of LRSE was reported to be preceded by increased linezolid consumption 13 and is widely considered to be linked to heavy linezolid usage. 6, 13 In recent years, LRSE have been described to exhibit partial dependence on linezolid, which is apparently due to structural adaptations of the ribosomes leading to faster protein synthesis rates and remarkably accelerated growth. 5 In Greece, linezoliddependent isolates were shown to represent the majority of LRSE and to belong exclusively to ST22, implying that the common administration of linezolid might have facilitated the selection and spread of this LRSE clone. In the current study, LRSE from five distantly located German hospitals also included a high proportion (10/14, 71.4%) of linezolid-dependent strains, which belonged mainly to ST22 (n " 7) and to a lesser extent to ST2 (n " 1), ST5 (n " 1) and ST168 (n " 1); of note, all these STs are related (https:// pubmlst.org/bigsdb?db"pubmlst_sepidermidis_isolates) and belong to clonal complex (CC) 5. This observation may imply the existence of inherent traits of this lineage that predispose to linezolid-dependent growth and remain to be discovered in future studies.
In conclusion, the multi-clonal dissemination of CC5 linezoliddependent LRSE in German hospitals, together with the predominance of ST22 linezolid-dependent LRSE in Greece, indicates that LRSE of CC5 and possibly other lineages commonly exhibit this phenotypic trait, which apparently provides selective advantage under linezolid exposure. Given that linezolid usage is quite common for the treatment of VRE, MRSA or vancomycin-intermediate S. aureus (VISA) infections, linezolid dependence may underlie the observed increasing number of isolations of LRSE in Europe. These observations necessitate further studies to identify the occurrence of linezolid-dependent LRSE worldwide. Finally, it appears that rational usage of linezolid is important to limit the selection of linezolid-dependent LRSE and preserve the activity of this drug.
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